

**Washington State Pharmacy and Therapeutics Committee**  
**Drug Utilization Review Board**  
**Date: June 16, 2021**  
**Time: 9 a.m. to 12:30 p.m.**  
**Zoom Webinar**

|            |  |                                   |
|------------|--|-----------------------------------|
| 9 a.m.     | Welcome & Introductions<br><br><b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>   | Ginni Buccola,<br>Committee Chair |
| 9:05 a.m.  | Asthma and COPD Agents: <ul style="list-style-type: none"> <li>• Anticholinergics</li> <li>• Phosphodiesterase 4 Inhibitors</li> <li>• Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations</li> <li>• Long Acting Muscarinic Agents <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>  | Umang Patel,<br>Magellan          |
| 9:20 a.m.  | Asthma and COPD Agents: <ul style="list-style-type: none"> <li>• Inhaled Corticosteroid Combinations</li> <li>• Inhaled Corticosteroid <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>  | Umang Patel,<br>Magellan          |
| 9:35 a.m.  | Asthma and COPD Agents: Monoclonal Antibodies <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Umang Patel,<br>Magellan          |
| 9:50 a.m.  | Hematopoietic Agents: Gaucher Disease <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Umang Patel,<br>Magellan          |
| 9:53 a.m.  | Hematopoietic Agents: Sickle Cell Anemia <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>  | Umang Patel,<br>Magellan          |
| 9:55 a.m.  | Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Umang Patel,<br>Magellan          |
| 10:10 a.m. | Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAs) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>  | Umang Patel,<br>Magellan          |
| 10:20 a.m. | Break  | All                               |
| 10:30 a.m. | Immune Modulators : Thalidomide Analogues<br>Oncology Agents : <ul style="list-style-type: none"> <li>• Alkylating Agents – Oral</li> <li>• Antineoplastics Misc – Oral</li> <li>• BCL-2 Inhibitors – Oral</li> <li>• Histone Deacetylase Inhibitors – Oral</li> <li>• Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral</li> <li>• Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral</li> </ul> | Umang Patel,<br>Magellan          |

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.

|            |   |                                |
|------------|---|--------------------------------|
|            | <ul style="list-style-type: none"> <li>• Janus Associated Kinase (JAK) Inhibitors – Oral</li> <li>• Proteasome Inhibitors – Oral</li> <li>• XPO1 Inhibitors - Oral</li> <li>• Antimetabolites – Oral</li> <li>• Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul> |                                |
| 11 a.m.    | Hematopoietic Agents: Thrombopoiesis (TPO) Stimulating Proteins <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>  | Umang Patel, Magellan          |
| 11:10 a.m. | Apple Health Policy: Edurant <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Marissa Tabile, HCA            |
| 11:30 a.m. | Apple Health Policy: Isotretinoin <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>  | Ryan Taketomo, HCA             |
| 11:50 a.m. | Apple Health Policy: Eucrisa <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>   | Marissa Tabile, HCA            |
| 12:10 p.m. | Apple Health Policy: Dupixent <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>  | Marissa Tabile, HCA            |
| 12:30 p.m. | <b>Drug Utilization Review Board Adjourns</b>   | Ginni Buccola, Committee Chair |

*For all Apple Health (Medicaid) questions, please email [AppleHealthPharmacyPolicy@hca.wa.gov](mailto:AppleHealthPharmacyPolicy@hca.wa.gov).*

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.